speb/financial-data huggingface dataset:
SMSPHARMA.NS balance_sheet (annual, 2023-03-31) — Total Non Current Liabilities Net Minority Interest: 1641714000.00
SMSPHARMA.NS income_statement (annual, 2023-03-31) — Total Other Finance Cost: 9798000.00
SMSPHARMA.NS income_statement (annual, 2023-03-31) — Total Unusual Items: -544000.00
SMSPHARMA.NS income_statement (annual, 2023-03-31) — Total Unusual Items Excluding Goodwill: -544000.00
SMSPHARMA.NS balance_sheet (annual, 2023-03-31) — Work In Process: 1059022000.00
SMSPHARMA.NS balance_sheet (annual, 2023-03-31) — Working Capital: 1557351000.00
SMSPHARMA.NS income_statement (annual, 2024-03-31) — +Operating Expense: 1235004000.00
SMSPHARMA.NS income_statement (annual, 2024-03-31) — +Total Revenue: 7064565000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Accounts Payable: 1513227000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Accounts Receivable: 2362332000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Accumulated Depreciation: -1897109000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Additional Paid In Capital: 713684000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Allowance For Doubtful Accounts Receivable: -1049000.00
SMSPHARMA.NS income_statement (annual, 2024-03-31) — Amortization: 9116000.00
SMSPHARMA.NS cash_flow (annual, 2024-03-31) — Amortization Cash Flow: 9116000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Available For Sale Securities: 187966000.00
SMSPHARMA.NS income_statement (annual, 2024-03-31) — Basic Average Shares: 84652030.00
SMSPHARMA.NS income_statement (annual, 2024-03-31) — Basic EPS: 5.89
SMSPHARMA.NS cash_flow (annual, 2024-03-31) — Beginning Cash Position: 73078000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Buildings And Improvements: 1341086000.00
SMSPHARMA.NS cash_flow (annual, 2024-03-31) — Capital Expenditure: -521600000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Capital Lease Obligations: 5918000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Capital Stock: 84652000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Cash And Cash Equivalents: 360395000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Cash Cash Equivalents And Short Term Investments: 361160000.00
SMSPHARMA.NS cash_flow (annual, 2024-03-31) — Cash Dividends Paid: -25396000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Cash Financial: 360395000.00
SMSPHARMA.NS cash_flow (annual, 2024-03-31) — Change In Inventory: -101984000.00
SMSPHARMA.NS cash_flow (annual, 2024-03-31) — Change In Other Current Assets: -88509000.00
SMSPHARMA.NS cash_flow (annual, 2024-03-31) — Change In Other Current Liabilities: 41744000.00
SMSPHARMA.NS cash_flow (annual, 2024-03-31) — Change In Payable: 438677000.00
SMSPHARMA.NS cash_flow (annual, 2024-03-31) — Change In Prepaid Assets: 43064000.00
SMSPHARMA.NS cash_flow (annual, 2024-03-31) — Change In Receivables: -878470000.00
SMSPHARMA.NS cash_flow (annual, 2024-03-31) — Change In Working Capital: -545478000.00
SMSPHARMA.NS cash_flow (annual, 2024-03-31) — Changes In Cash: 287317000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Common Stock: 84652000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Common Stock Equity: 5363289000.00
SMSPHARMA.NS cash_flow (annual, 2024-03-31) — Common Stock Issuance: 284778000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Construction In Progress: 441429000.00
SMSPHARMA.NS income_statement (annual, 2024-03-31) — Cost Of Revenue: 4977079000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Current Assets: 5338948000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Current Capital Lease Obligation: 5918000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Current Debt: 1580924000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Current Debt And Capital Lease Obligation: 1586842000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Current Liabilities: 3317184000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Current Provisions: 10304000.00
SMSPHARMA.NS cash_flow (annual, 2024-03-31) — Depreciation: 306041000.00
SMSPHARMA.NS cash_flow (annual, 2024-03-31) — Depreciation And Amortization: 315157000.00
SMSPHARMA.NS income_statement (annual, 2024-03-31) — Depreciation And Amortization In Income Statement: 315157000.00
SMSPHARMA.NS income_statement (annual, 2024-03-31) — Depreciation Income Statement: 306041000.00
SMSPHARMA.NS income_statement (annual, 2024-03-31) — Diluted Average Shares: 84652030.00
SMSPHARMA.NS income_statement (annual, 2024-03-31) — Diluted EPS: 5.89
SMSPHARMA.NS income_statement (annual, 2024-03-31) — Diluted NI Availto Com Stockholders: 498260000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Dividends Payable: 865000.00
SMSPHARMA.NS income_statement (annual, 2024-03-31) — EBIT: 887245000.00
SMSPHARMA.NS income_statement (annual, 2024-03-31) — EBITDA: 1202402000.00
SMSPHARMA.NS cash_flow (annual, 2024-03-31) — End Cash Position: 360395000.00
SMSPHARMA.NS cash_flow (annual, 2024-03-31) — Financing Cash Flow: 306790000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Finished Goods: 548189000.00
SMSPHARMA.NS cash_flow (annual, 2024-03-31) — Free Cash Flow: -20353000.00
SMSPHARMA.NS cash_flow (annual, 2024-03-31) — Gain Loss On Investment Securities: -373000.00
SMSPHARMA.NS income_statement (annual, 2024-03-31) — General And Administrative Expense: 94742000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Goodwill And Other Intangible Assets: 26595000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Gross Accounts Receivable: 2363381000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Gross PPE: 6684526000.00
SMSPHARMA.NS income_statement (annual, 2024-03-31) — Gross Profit: 2087486000.00
SMSPHARMA.NS income_statement (annual, 2024-03-31) — Interest Expense: 226177000.00
SMSPHARMA.NS income_statement (annual, 2024-03-31) — Interest Expense Non Operating: 226177000.00
SMSPHARMA.NS income_statement (annual, 2024-03-31) — Interest Income: 7579000.00
SMSPHARMA.NS income_statement (annual, 2024-03-31) — Interest Income Non Operating: 7579000.00
SMSPHARMA.NS cash_flow (annual, 2024-03-31) — Interest Paid Cff: -217516000.00
SMSPHARMA.NS cash_flow (annual, 2024-03-31) — Interest Received Cfi: 1587000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Inventory: 2336978000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Invested Capital: 8165076000.00
SMSPHARMA.NS cash_flow (annual, 2024-03-31) — Investing Cash Flow: -520720000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Investmentin Financial Assets: 187966000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Investmentsin Associatesat Cost: 109378000.00
SMSPHARMA.NS cash_flow (annual, 2024-03-31) — Issuance Of Capital Stock: 284778000.00
SMSPHARMA.NS cash_flow (annual, 2024-03-31) — Issuance Of Debt: 652934000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Land And Improvements: 42130000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Long Term Capital Lease Obligation: 0.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Long Term Debt: 1220863000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Long Term Debt And Capital Lease Obligation: 1220863000.00
SMSPHARMA.NS cash_flow (annual, 2024-03-31) — Long Term Debt Issuance: 450863000.00
SMSPHARMA.NS cash_flow (annual, 2024-03-31) — Long Term Debt Payments: -377636000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Long Term Equity Investment: 109378000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Long Term Provisions: 11601000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Machinery Furniture Equipment: 4576993000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Minority Interest: 0.00
SMSPHARMA.NS income_statement (annual, 2024-03-31) — Minority Interests: 0.00
SMSPHARMA.NS cash_flow (annual, 2024-03-31) — Net Common Stock Issuance: 284778000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Net Debt: 2441392000.00
SMSPHARMA.NS income_statement (annual, 2024-03-31) — Net Income: 498260000.00
SMSPHARMA.NS income_statement (annual, 2024-03-31) — Net Income Common Stockholders: 498260000.00
SMSPHARMA.NS income_statement (annual, 2024-03-31) — Net Income Continuous Operations: 498260000.00
SMSPHARMA.NS income_statement (annual, 2024-03-31) — Net Income From Continuing And Discontinued Operation: 498260000.00
SMSPHARMA.NS income_statement (annual, 2024-03-31) — Net Income From Continuing Operation Net Minority Interest: 498260000.00
SMSPHARMA.NS cash_flow (annual, 2024-03-31) — Net Income From Continuing Operations: 661068000.00
SMSPHARMA.NS income_statement (annual, 2024-03-31) — Net Income Including Noncontrolling Interests: 498260000.00
SMSPHARMA.NS income_statement (annual, 2024-03-31) — Net Interest Income: -228378000.00
SMSPHARMA.NS cash_flow (annual, 2024-03-31) — Net Investment Purchase And Sale: -65000.00
SMSPHARMA.NS cash_flow (annual, 2024-03-31) — Net Issuance Payments Of Debt: 275298000.00
SMSPHARMA.NS cash_flow (annual, 2024-03-31) — Net Long Term Debt Issuance: 73227000.00
SMSPHARMA.NS income_statement (annual, 2024-03-31) — Net Non Operating Interest Income Expense: -228378000.00
SMSPHARMA.NS cash_flow (annual, 2024-03-31) — Net Other Investing Changes: -1522000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Net PPE: 4787417000.00
SMSPHARMA.NS cash_flow (annual, 2024-03-31) — Net PPE Purchase And Sale: -520720000.00
SMSPHARMA.NS cash_flow (annual, 2024-03-31) — Net Short Term Debt Issuance: 202071000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Net Tangible Assets: 5336694000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Taxes Liabilities: 427989000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 11601000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Non Current Prepaid Assets: 51705000.00
SMSPHARMA.NS income_statement (annual, 2024-03-31) — Normalized EBITDA: 1202030000.00
SMSPHARMA.NS income_statement (annual, 2024-03-31) — Normalized Income: 497983138.92
SMSPHARMA.NS cash_flow (annual, 2024-03-31) — Operating Cash Flow: 501247000.00
SMSPHARMA.NS income_statement (annual, 2024-03-31) — Operating Income: 852482000.00
SMSPHARMA.NS income_statement (annual, 2024-03-31) — Operating Revenue: 7064565000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Ordinary Shares Number: 84652030.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Current Assets: 227545000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Current Liabilities: 48295000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Equity Interest: 285750000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Intangible Assets: 26595000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Inventories: 6747000.00
SMSPHARMA.NS cash_flow (annual, 2024-03-31) — Other Non Cash Items: 224657000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Non Current Assets: 138712000.00
SMSPHARMA.NS income_statement (annual, 2024-03-31) — Other Non Operating Income Expenses: 7617000.00
SMSPHARMA.NS income_statement (annual, 2024-03-31) — Other Operating Expenses: 52512000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Payable: 186177000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Properties: 282888000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Receivables: 18638000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Short Term Investments: 765000.00
SMSPHARMA.NS income_statement (annual, 2024-03-31) — Other Special Charges: -372000.00
SMSPHARMA.NS income_statement (annual, 2024-03-31) — Otherunder Preferred Stock Dividend: 0.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Payables: 1700269000.00
SMSPHARMA.NS cash_flow (annual, 2024-03-31) — Pension And Employee Benefit Expense: -2033000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 10304000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Prepaid Assets: 148351000.00
SMSPHARMA.NS income_statement (annual, 2024-03-31) — Pretax Income: 661068000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Properties: 0.00
SMSPHARMA.NS cash_flow (annual, 2024-03-31) — Purchase Of Investment: -65000.00
SMSPHARMA.NS cash_flow (annual, 2024-03-31) — Purchase Of PPE: -521600000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Raw Materials: 877383000.00
SMSPHARMA.NS income_statement (annual, 2024-03-31) — Reconciled Cost Of Revenue: 4977079000.00
SMSPHARMA.NS income_statement (annual, 2024-03-31) — Reconciled Depreciation: 315157000.00
SMSPHARMA.NS income_statement (annual, 2024-03-31) — Rent And Landing Fees: 717000.00
SMSPHARMA.NS income_statement (annual, 2024-03-31) — Rent Expense Supplemental: 717000.00
SMSPHARMA.NS cash_flow (annual, 2024-03-31) — Repayment Of Debt: -377636000.00
SMSPHARMA.NS income_statement (annual, 2024-03-31) — Research And Development: 111131000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Restricted Cash: 865000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Retained Earnings: 3248775000.00
SMSPHARMA.NS cash_flow (annual, 2024-03-31) — Sale Of PPE: 880000.00
SMSPHARMA.NS income_statement (annual, 2024-03-31) — Selling And Marketing Expense: 47317000.00
SMSPHARMA.NS income_statement (annual, 2024-03-31) — Selling General And Administration: 142059000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Share Issued: 84652030.00
SMSPHARMA.NS cash_flow (annual, 2024-03-31) — Short Term Debt Issuance: 202071000.00
SMSPHARMA.NS income_statement (annual, 2024-03-31) — Special Income Charges: 372000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Stockholders Equity: 5363289000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Tangible Book Value: 5336694000.00
SMSPHARMA.NS income_statement (annual, 2024-03-31) — Tax Effect Of Unusual Items: 95138.92
SMSPHARMA.NS income_statement (annual, 2024-03-31) — Tax Provision: 169068000.00
SMSPHARMA.NS income_statement (annual, 2024-03-31) — Tax Rate For Calcs: 0.26
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Taxes Receivable: 110624000.00
SMSPHARMA.NS cash_flow (annual, 2024-03-31) — Taxes Refund Paid: -154000000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Total Assets: 10340926000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Total Capitalization: 6584152000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Total Debt: 2807705000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Total Equity Gross Minority Interest: 5363289000.00
SMSPHARMA.NS income_statement (annual, 2024-03-31) — Total Expenses: 6212083000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Total Liabilities Net Minority Interest: 4977637000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Total Non Current Assets: 5001978000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Total Non Current Liabilities Net Minority Interest: 1660453000.00
SMSPHARMA.NS income_statement (annual, 2024-03-31) — Total Other Finance Cost: 9780000.00
SMSPHARMA.NS income_statement (annual, 2024-03-31) — Total Unusual Items: 372000.00
SMSPHARMA.NS income_statement (annual, 2024-03-31) — Total Unusual Items Excluding Goodwill: 372000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Treasury Shares Number: 0.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Work In Process: 904659000.00
SMSPHARMA.NS balance_sheet (annual, 2024-03-31) — Working Capital: 2021764000.00
SMSPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Accounts Payable: 2151316000.00
SMSPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Accounts Receivable: 2133788000.00
SMSPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Available For Sale Securities: 195483000.00
SMSPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Capital Lease Obligations: 1731000.00
SMSPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Capital Stock: 84652000.00
SMSPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Cash And Cash Equivalents: 89006000.00
SMSPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Cash Cash Equivalents And Short Term Investments: 208911000.00
SMSPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Common Stock: 84652000.00
SMSPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Common Stock Equity: 5635498000.00
SMSPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Construction In Progress: 944964000.00
SMSPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Current Assets: 5819422000.00
SMSPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Current Capital Lease Obligation: 1731000.00
SMSPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Current Debt: 1345569000.00
SMSPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Current Debt And Capital Lease Obligation: 1347300000.00
SMSPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Current Liabilities: 3753988000.00
SMSPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Current Provisions: 10660000.00
SMSPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Goodwill And Other Intangible Assets: 24639000.00
SMSPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Gross PPE: 5184058000.00
SMSPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Inventory: 3152716000.00
SMSPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Invested Capital: 8487199000.00
SMSPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Investmentin Financial Assets: 195483000.00
SMSPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Long Term Capital Lease Obligation: 0.00
SMSPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Long Term Debt: 1506132000.00
SMSPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Long Term Debt And Capital Lease Obligation: 1506132000.00
SMSPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Long Term Provisions: 12300000.00
SMSPHARMA.NS income_statement (quarterly, 2024-09-30) — Minority Interests: 0.00
SMSPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Net Debt: 2762695000.00
SMSPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Net PPE: 5184058000.00
SMSPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Net Tangible Assets: 5610859000.00
SMSPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Non Current Deferred Taxes Liabilities: 439364000.00
SMSPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Ordinary Shares Number: 84652030.00
SMSPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Current Assets: 311285000.00
SMSPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Current Liabilities: 56979000.00
SMSPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Equity Interest: 5550846000.00
SMSPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Non Current Assets: 123680000.00
SMSPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Properties: 4239094000.00
SMSPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Short Term Investments: 119905000.00
SMSPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Payables: 2151316000.00
SMSPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Share Issued: 84652030.00
SMSPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Stockholders Equity: 5635498000.00
SMSPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Tangible Book Value: 5610859000.00
SMSPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Taxes Receivable: 12722000.00
SMSPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Assets: 11347282000.00
SMSPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Capitalization: 7141630000.00
SMSPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Debt: 2853432000.00
SMSPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Equity Gross Minority Interest: 5635498000.00
SMSPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Liabilities Net Minority Interest: 5711784000.00
SMSPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Assets: 5527860000.00
SMSPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Liabilities Net Minority Interest: 1957796000.00
SMSPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Working Capital: 2065434000.00
SMSPHARMA.NS income_statement (quarterly, 2024-12-31) — Minority Interests: 0.00
SMSPHARMA.NS income_statement (annual, 2025-03-31) — +Operating Expense: 1600413000.00
SMSPHARMA.NS income_statement (quarterly, 2025-03-31) — +Operating Expense: 442864000.00
SMSPHARMA.NS income_statement (annual, 2025-03-31) — +Total Revenue: 7827481000.00
SMSPHARMA.NS income_statement (quarterly, 2025-03-31) — +Total Revenue: 2481956000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Accounts Payable: 1139168000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 1139168000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Accounts Receivable: 2032336000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 2032336000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Accumulated Depreciation: -2222285000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Accumulated Depreciation: -2222285000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Additional Paid In Capital: 1217684000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 1217684000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -1049000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -1049000.00
SMSPHARMA.NS income_statement (annual, 2025-03-31) — Amortization: 7993000.00
SMSPHARMA.NS cash_flow (annual, 2025-03-31) — Amortization Cash Flow: 7993000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Available For Sale Securities: 215720000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Available For Sale Securities: 215720000.00
SMSPHARMA.NS income_statement (annual, 2025-03-31) — Basic Average Shares: 84724265.00
SMSPHARMA.NS income_statement (quarterly, 2025-03-31) — Basic Average Shares: 84645000.00
SMSPHARMA.NS income_statement (annual, 2025-03-31) — Basic EPS: 8.16
SMSPHARMA.NS income_statement (quarterly, 2025-03-31) — Basic EPS: 2.40
SMSPHARMA.NS cash_flow (annual, 2025-03-31) — Beginning Cash Position: 360395000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Buildings And Improvements: 1566021000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Buildings And Improvements: 1566021000.00
SMSPHARMA.NS cash_flow (annual, 2025-03-31) — Capital Expenditure: -1233799000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Capital Lease Obligations: 0.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Capital Lease Obligations: 0.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Capital Stock: 88652000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Capital Stock: 88652000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Cash And Cash Equivalents: 413991000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 413991000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 414905000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 414905000.00
SMSPHARMA.NS cash_flow (annual, 2025-03-31) — Cash Dividends Paid: -33861000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Cash Financial: 413991000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Cash Financial: 413991000.00
SMSPHARMA.NS cash_flow (annual, 2025-03-31) — Change In Inventory: -510314000.00
SMSPHARMA.NS cash_flow (annual, 2025-03-31) — Change In Other Current Assets: 46436000.00
SMSPHARMA.NS cash_flow (annual, 2025-03-31) — Change In Other Current Liabilities: 61823000.00
SMSPHARMA.NS cash_flow (annual, 2025-03-31) — Change In Payable: -374059000.00
SMSPHARMA.NS cash_flow (annual, 2025-03-31) — Change In Prepaid Assets: 15339000.00
SMSPHARMA.NS cash_flow (annual, 2025-03-31) — Change In Receivables: 329996000.00
SMSPHARMA.NS cash_flow (annual, 2025-03-31) — Change In Working Capital: -430779000.00
SMSPHARMA.NS cash_flow (annual, 2025-03-31) — Changes In Cash: 53596000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Common Stock: 88652000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Common Stock: 88652000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Common Stock Equity: 6396443000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 6396443000.00
SMSPHARMA.NS cash_flow (annual, 2025-03-31) — Common Stock Issuance: 380903000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Construction In Progress: 436637000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Construction In Progress: 436637000.00
SMSPHARMA.NS income_statement (annual, 2025-03-31) — Cost Of Revenue: 5180528000.00
SMSPHARMA.NS income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 1717433000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Current Assets: 5544680000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Current Assets: 5544680000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Current Capital Lease Obligation: 0.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Current Capital Lease Obligation: 0.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Current Debt: 1713915000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Current Debt: 1713915000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Current Debt And Capital Lease Obligation: 1713915000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 1713915000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Current Liabilities: 3243686000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 3243686000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Current Provisions: 11080000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Current Provisions: 11080000.00
SMSPHARMA.NS cash_flow (annual, 2025-03-31) — Depreciation: 343373000.00
SMSPHARMA.NS cash_flow (annual, 2025-03-31) — Depreciation And Amortization: 343373000.00
SMSPHARMA.NS income_statement (annual, 2025-03-31) — Depreciation And Amortization In Income Statement: 343373000.00
SMSPHARMA.NS income_statement (quarterly, 2025-03-31) — Depreciation And Amortization In Income Statement: 86399000.00
SMSPHARMA.NS income_statement (annual, 2025-03-31) — Depreciation Income Statement: 343373000.00
SMSPHARMA.NS income_statement (quarterly, 2025-03-31) — Depreciation Income Statement: 86399000.00
SMSPHARMA.NS income_statement (annual, 2025-03-31) — Diluted Average Shares: 84724265.00
SMSPHARMA.NS income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 84645000.00
SMSPHARMA.NS income_statement (annual, 2025-03-31) — Diluted EPS: 8.16
SMSPHARMA.NS income_statement (quarterly, 2025-03-31) — Diluted EPS: 2.40
SMSPHARMA.NS income_statement (annual, 2025-03-31) — Diluted NI Availto Com Stockholders: 691350000.00
SMSPHARMA.NS income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: 203148000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Dividends Payable: 956000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Dividends Payable: 956000.00
SMSPHARMA.NS income_statement (annual, 2025-03-31) — EBIT: 1108784000.00
SMSPHARMA.NS income_statement (quarterly, 2025-03-31) — EBIT: 335900000.00
SMSPHARMA.NS income_statement (annual, 2025-03-31) — EBITDA: 1452157000.00
SMSPHARMA.NS income_statement (quarterly, 2025-03-31) — EBITDA: 422299000.00
SMSPHARMA.NS cash_flow (annual, 2025-03-31) — End Cash Position: 413991000.00
SMSPHARMA.NS cash_flow (annual, 2025-03-31) — Financing Cash Flow: 470792000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Finished Goods: 839712000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Finished Goods: 839712000.00
SMSPHARMA.NS cash_flow (annual, 2025-03-31) — Free Cash Flow: -416706000.00
SMSPHARMA.NS cash_flow (annual, 2025-03-31) — Gain Loss On Investment Securities: -205000.00
SMSPHARMA.NS income_statement (annual, 2025-03-31) — General And Administrative Expense: 74195000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Goodwill And Other Intangible Assets: 21296000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 21296000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Gross Accounts Receivable: 2033385000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Gross Accounts Receivable: 2033385000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Gross PPE: 7967401000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Gross PPE: 7967401000.00
SMSPHARMA.NS income_statement (annual, 2025-03-31) — Gross Profit: 2646953000.00
SMSPHARMA.NS income_statement (quarterly, 2025-03-31) — Gross Profit: 764523000.00
SMSPHARMA.NS income_statement (annual, 2025-03-31) — Interest Expense: 185409000.00
SMSPHARMA.NS income_statement (quarterly, 2025-03-31) — Interest Expense: 50651000.00
SMSPHARMA.NS income_statement (annual, 2025-03-31) — Interest Expense Non Operating: 185409000.00
SMSPHARMA.NS income_statement (quarterly, 2025-03-31) — Interest Expense Non Operating: 50651000.00
SMSPHARMA.NS income_statement (annual, 2025-03-31) — Interest Income: 6869000.00
SMSPHARMA.NS income_statement (annual, 2025-03-31) — Interest Income Non Operating: 6869000.00
SMSPHARMA.NS cash_flow (annual, 2025-03-31) — Interest Paid Cff: -173529000.00
SMSPHARMA.NS cash_flow (annual, 2025-03-31) — Interest Received Cfi: 1668000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Inventory: 2847292000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Inventory: 2847292000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Invested Capital: 9504000000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Invested Capital: 9504000000.00
SMSPHARMA.NS cash_flow (annual, 2025-03-31) — Investing Cash Flow: -1234289000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Investmentin Financial Assets: 215720000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Investmentin Financial Assets: 215720000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Investmentsin Associatesat Cost: 116791000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Investmentsin Associatesat Cost: 116791000.00
SMSPHARMA.NS cash_flow (annual, 2025-03-31) — Issuance Of Capital Stock: 380903000.00
SMSPHARMA.NS cash_flow (annual, 2025-03-31) — Issuance Of Debt: 745267000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Land And Improvements: 42130000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Land And Improvements: 42130000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Long Term Capital Lease Obligation: 0.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Long Term Capital Lease Obligation: 0.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Long Term Debt: 1393642000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Long Term Debt: 1393642000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 1393642000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 1393642000.00
SMSPHARMA.NS cash_flow (annual, 2025-03-31) — Long Term Debt Issuance: 637238000.00
SMSPHARMA.NS cash_flow (annual, 2025-03-31) — Long Term Debt Payments: -440966000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Long Term Equity Investment: 116791000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Long Term Equity Investment: 116791000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Long Term Provisions: 12065000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Long Term Provisions: 12065000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Machinery Furniture Equipment: 5624228000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Machinery Furniture Equipment: 5624228000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Minority Interest: 1000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Minority Interest: 1000.00
SMSPHARMA.NS income_statement (annual, 2025-03-31) — Minority Interests: 6000.00
SMSPHARMA.NS cash_flow (annual, 2025-03-31) — Net Common Stock Issuance: 380903000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Net Debt: 2693566000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Net Debt: 2693566000.00
SMSPHARMA.NS income_statement (annual, 2025-03-31) — Net Income: 691350000.00
SMSPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Income: 203148000.00
SMSPHARMA.NS income_statement (annual, 2025-03-31) — Net Income Common Stockholders: 691350000.00
SMSPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: 203148000.00
SMSPHARMA.NS income_statement (annual, 2025-03-31) — Net Income Continuous Operations: 691348000.00
SMSPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: 203148000.00
SMSPHARMA.NS income_statement (annual, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 691350000.00
SMSPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 203148000.00
SMSPHARMA.NS income_statement (annual, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 691350000.00
SMSPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 203148000.00
SMSPHARMA.NS cash_flow (annual, 2025-03-31) — Net Income From Continuing Operations: 923375000.00
SMSPHARMA.NS income_statement (annual, 2025-03-31) — Net Income Including Noncontrolling Interests: 691348000.00
SMSPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: 203148000.00
SMSPHARMA.NS income_statement (annual, 2025-03-31) — Net Interest Income: -185409000.00
SMSPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Interest Income: -50651000.00
SMSPHARMA.NS cash_flow (annual, 2025-03-31) — Net Investment Purchase And Sale: -149000.00
SMSPHARMA.NS cash_flow (annual, 2025-03-31) — Net Issuance Payments Of Debt: 304301000.00
SMSPHARMA.NS cash_flow (annual, 2025-03-31) — Net Long Term Debt Issuance: 196272000.00
SMSPHARMA.NS income_statement (annual, 2025-03-31) — Net Non Operating Interest Income Expense: -185409000.00
SMSPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: -50651000.00
SMSPHARMA.NS cash_flow (annual, 2025-03-31) — Net Other Investing Changes: -2569000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Net PPE: 5745116000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Net PPE: 5745116000.00
SMSPHARMA.NS cash_flow (annual, 2025-03-31) — Net PPE Purchase And Sale: -1233239000.00
SMSPHARMA.NS cash_flow (annual, 2025-03-31) — Net Short Term Debt Issuance: 108029000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Net Tangible Assets: 6375147000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 6375147000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Taxes Liabilities: 480976000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Liabilities: 480976000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 12065000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 12065000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Non Current Prepaid Assets: 69478000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Non Current Prepaid Assets: 69478000.00
SMSPHARMA.NS income_statement (annual, 2025-03-31) — Normalized EBITDA: 1452157000.00
SMSPHARMA.NS income_statement (quarterly, 2025-03-31) — Normalized EBITDA: 422299000.00
SMSPHARMA.NS income_statement (annual, 2025-03-31) — Normalized Income: 691350000.00
SMSPHARMA.NS income_statement (quarterly, 2025-03-31) — Normalized Income: 203148000.00
SMSPHARMA.NS cash_flow (annual, 2025-03-31) — Operating Cash Flow: 817093000.00
SMSPHARMA.NS income_statement (annual, 2025-03-31) — Operating Income: 1046540000.00
SMSPHARMA.NS income_statement (quarterly, 2025-03-31) — Operating Income: 321659000.00
SMSPHARMA.NS income_statement (annual, 2025-03-31) — Operating Revenue: 7827481000.00
SMSPHARMA.NS income_statement (quarterly, 2025-03-31) — Operating Revenue: 2481956000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Ordinary Shares Number: 88652030.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 88652030.00
SMSPHARMA.NS cash_flow (annual, 2025-03-31) — Other Cash Adjustment Outside Changein Cash: -1000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Current Assets: 146394000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Current Assets: 146394000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Current Liabilities: 45851000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Current Liabilities: 45851000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Equity Interest: 158750000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Equity Interest: 158750000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Intangible Assets: 21296000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Intangible Assets: 21296000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Inventories: 9321000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Inventories: 9321000.00
SMSPHARMA.NS cash_flow (annual, 2025-03-31) — Other Non Cash Items: 173704000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Non Current Assets: 89923000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Non Current Assets: 89923000.00
SMSPHARMA.NS income_statement (annual, 2025-03-31) — Other Non Operating Income Expenses: 62244000.00
SMSPHARMA.NS income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: 14241000.00
SMSPHARMA.NS income_statement (annual, 2025-03-31) — Other Operating Expenses: 456198000.00
SMSPHARMA.NS income_statement (quarterly, 2025-03-31) — Other Operating Expenses: 90165000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Payable: 373750000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Payable: 373750000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Properties: 298385000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Properties: 298385000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Receivables: 15521000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Receivables: 15521000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Short Term Investments: 914000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Short Term Investments: 914000.00
SMSPHARMA.NS income_statement (annual, 2025-03-31) — Other Special Charges: -205000.00
SMSPHARMA.NS income_statement (annual, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
SMSPHARMA.NS income_statement (quarterly, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Payables: 1513874000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Payables: 1513874000.00
SMSPHARMA.NS cash_flow (annual, 2025-03-31) — Pension And Employee Benefit Expense: -3794000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 11080000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 11080000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Prepaid Assets: 87059000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Prepaid Assets: 87059000.00
SMSPHARMA.NS income_statement (annual, 2025-03-31) — Pretax Income: 923375000.00
SMSPHARMA.NS income_statement (quarterly, 2025-03-31) — Pretax Income: 285249000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Properties: 0.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Properties: 0.00
SMSPHARMA.NS cash_flow (annual, 2025-03-31) — Purchase Of Investment: -149000.00
SMSPHARMA.NS cash_flow (annual, 2025-03-31) — Purchase Of PPE: -1233799000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Raw Materials: 736983000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Raw Materials: 736983000.00
SMSPHARMA.NS income_statement (annual, 2025-03-31) — Reconciled Cost Of Revenue: 5180528000.00
SMSPHARMA.NS income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 1717433000.00
SMSPHARMA.NS income_statement (annual, 2025-03-31) — Reconciled Depreciation: 343373000.00
SMSPHARMA.NS income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 86399000.00
SMSPHARMA.NS income_statement (annual, 2025-03-31) — Rent And Landing Fees: 4172000.00
SMSPHARMA.NS income_statement (annual, 2025-03-31) — Rent Expense Supplemental: 4172000.00
SMSPHARMA.NS cash_flow (annual, 2025-03-31) — Repayment Of Debt: -440966000.00
SMSPHARMA.NS income_statement (annual, 2025-03-31) — Research And Development: 128306000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Restricted Cash: 956000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Restricted Cash: 956000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Retained Earnings: 3800929000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Retained Earnings: 3800929000.00
SMSPHARMA.NS cash_flow (annual, 2025-03-31) — Sale Of PPE: 560000.00
SMSPHARMA.NS income_statement (annual, 2025-03-31) — Selling And Marketing Expense: 137531000.00
SMSPHARMA.NS income_statement (annual, 2025-03-31) — Selling General And Administration: 211726000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Share Issued: 88652030.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Share Issued: 88652030.00
SMSPHARMA.NS cash_flow (annual, 2025-03-31) — Short Term Debt Issuance: 108029000.00
SMSPHARMA.NS income_statement (annual, 2025-03-31) — Special Income Charges: 0.00
SMSPHARMA.NS income_statement (quarterly, 2025-03-31) — Special Income Charges: 0.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Stockholders Equity: 6396443000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 6396443000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Tangible Book Value: 6375147000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 6375147000.00
SMSPHARMA.NS income_statement (annual, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
SMSPHARMA.NS income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
SMSPHARMA.NS income_statement (annual, 2025-03-31) — Tax Provision: 249393000.00
SMSPHARMA.NS income_statement (quarterly, 2025-03-31) — Tax Provision: 84420000.00
SMSPHARMA.NS income_statement (annual, 2025-03-31) — Tax Rate For Calcs: 0.27
SMSPHARMA.NS income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.30
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Taxes Receivable: 146611000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Taxes Receivable: 146611000.00
SMSPHARMA.NS cash_flow (annual, 2025-03-31) — Taxes Refund Paid: -198334000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Assets: 11526813000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Assets: 11526813000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Capitalization: 7790085000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 7790085000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Debt: 3107557000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Debt: 3107557000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Equity Gross Minority Interest: 6396444000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 6396444000.00
SMSPHARMA.NS income_statement (annual, 2025-03-31) — Total Expenses: 6780941000.00
SMSPHARMA.NS income_statement (quarterly, 2025-03-31) — Total Expenses: 2160297000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Liabilities Net Minority Interest: 5130369000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 5130369000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Non Current Assets: 5982133000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 5982133000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 1886683000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 1886683000.00
SMSPHARMA.NS income_statement (annual, 2025-03-31) — Total Other Finance Cost: 11061000.00
SMSPHARMA.NS income_statement (annual, 2025-03-31) — Total Unusual Items: 0.00
SMSPHARMA.NS income_statement (quarterly, 2025-03-31) — Total Unusual Items: 0.00
SMSPHARMA.NS income_statement (annual, 2025-03-31) — Total Unusual Items Excluding Goodwill: 0.00
SMSPHARMA.NS income_statement (quarterly, 2025-03-31) — Total Unusual Items Excluding Goodwill: 0.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Work In Process: 1261276000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Work In Process: 1261276000.00
SMSPHARMA.NS balance_sheet (annual, 2025-03-31) — Working Capital: 2300994000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Working Capital: 2300994000.00
SMSPHARMA.NS income_statement (quarterly, 2025-06-30) — +Operating Expense: 357319000.00
SMSPHARMA.NS income_statement (quarterly, 2025-06-30) — +Total Revenue: 1960471000.00
SMSPHARMA.NS income_statement (quarterly, 2025-06-30) — Basic Average Shares: 88703463.00
SMSPHARMA.NS income_statement (quarterly, 2025-06-30) — Basic EPS: 2.31
SMSPHARMA.NS income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 1306986000.00
SMSPHARMA.NS income_statement (quarterly, 2025-06-30) — Depreciation And Amortization In Income Statement: 97525000.00
SMSPHARMA.NS income_statement (quarterly, 2025-06-30) — Depreciation Income Statement: 97525000.00
SMSPHARMA.NS income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 88703463.00
SMSPHARMA.NS income_statement (quarterly, 2025-06-30) — Diluted EPS: 2.31
SMSPHARMA.NS income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: 204905000.00
SMSPHARMA.NS income_statement (quarterly, 2025-06-30) — EBIT: 302097000.00
SMSPHARMA.NS income_statement (quarterly, 2025-06-30) — EBITDA: 399622000.00
SMSPHARMA.NS income_statement (quarterly, 2025-06-30) — Gross Profit: 653485000.00
SMSPHARMA.NS income_statement (quarterly, 2025-06-30) — Interest Expense: 58407000.00
SMSPHARMA.NS income_statement (quarterly, 2025-06-30) — Interest Expense Non Operating: 58407000.00
SMSPHARMA.NS income_statement (quarterly, 2025-06-30) — Minority Interests: 0.00
SMSPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Income: 204905000.00
SMSPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: 204905000.00
SMSPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: 204905000.00
SMSPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: 204905000.00
SMSPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: 204905000.00
SMSPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: 204905000.00
SMSPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Interest Income: -58407000.00
SMSPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: -58407000.00
SMSPHARMA.NS income_statement (quarterly, 2025-06-30) — Normalized EBITDA: 399622000.00
SMSPHARMA.NS income_statement (quarterly, 2025-06-30) — Normalized Income: 204905000.00
SMSPHARMA.NS income_statement (quarterly, 2025-06-30) — Operating Income: 296166000.00
SMSPHARMA.NS income_statement (quarterly, 2025-06-30) — Operating Revenue: 1960471000.00
SMSPHARMA.NS income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: 5931000.00
SMSPHARMA.NS income_statement (quarterly, 2025-06-30) — Other Operating Expenses: 77945000.00
SMSPHARMA.NS income_statement (quarterly, 2025-06-30) — Otherunder Preferred Stock Dividend: 0.00
SMSPHARMA.NS income_statement (quarterly, 2025-06-30) — Pretax Income: 243690000.00
SMSPHARMA.NS income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 1306986000.00
SMSPHARMA.NS income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 97525000.00
SMSPHARMA.NS income_statement (quarterly, 2025-06-30) — Special Income Charges: 0.00
SMSPHARMA.NS income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 0.00
SMSPHARMA.NS income_statement (quarterly, 2025-06-30) — Tax Provision: 56543000.00
SMSPHARMA.NS income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.23